Malaysian VC Xeraya Capital joins US biotech firm InterVenn’s US$34M round

Malaysian VC firm Xeraya Capital is among the investors who have participated in the US$34 million Series B financing round of InterVenn Biosciences, a US-based precision medicine firm. US-based Anzu Partners led the oversubscribed round. Genoa Ventures, Amplify Partners, True Ventures, and the Ojjeh Family, are the other participants. InterVenn will use the funds to […] The post Malaysian VC Xeraya Capital joins US biotech firm InterVenn’s US$34M round appeared first on e27.